On the other hand, CXCL13 saliva levels were increased in SSL patients (34.92 pg/ml) compared to non-SS NHLs (6.92 pg/ml, p=0.0065), but were not significantly different from those in other study groups (18.57, 18.70 and 14.19 pg/ml in pSS, sicca-complaining controls and healthy individuals, respectively) (Figure 2B). This evidence concerns the gene CXCL13 and synovial sarcoma.